Tg Therapeutics (TGTX) Non-Current Deferred Tax Liability (2022 - 2024)

Tg Therapeutics' Non-Current Deferred Tax Liability history runs 3 years deep, the most recent figure standing at $6.2 million for Q4 2024.

• In Q4 2024, Non-Current Deferred Tax Liability fell 89.97% year-over-year to $6.2 million; the TTM figure through Dec 2024 stood at $6.2 million (down 89.97% YoY), while the FY2024 annual figure was $6.2 million, down 89.97% from the prior year.
• Non-Current Deferred Tax Liability for Q4 2024 stood at $6.2 million, down from $61.8 million in the prior quarter.
• The five-year high for Non-Current Deferred Tax Liability was $61.8 million in Q4 2023, with the low at $6.2 million in Q4 2024.
• The 3-year median for Non-Current Deferred Tax Liability is $38.5 million (2022), against an average of $35.5 million.
• The sharpest annual moves came in 2023 and 2024: Non-Current Deferred Tax Liability jumped 60.52% in 2023, then slumped 89.97% in 2024.
• Tg Therapeutics' Non-Current Deferred Tax Liability stood at $38.5 million in 2022, then surged by 60.52% to $61.8 million in 2023, then plunged by 89.97% to $6.2 million in 2024.
• Business Quant data shows TGTX's Non-Current Deferred Tax Liability at $6.2 million in Q4 2024, $61.8 million in Q4 2023, and $38.5 million in Q4 2022.